TORONTO, August 14, 2025 – TheNewswire - (StageZero Life Sciences, Ltd. (the “Company” or “StageZero”) (TSX: SZLS) announces that its application for listing on the NEX Exchange (“NEX”) has been approved and its stock will be listed effective at the opening August 15, 2025 under the symbol SZLS.H but remain subject to a trading suspension under the Failure to File Cease Trade Order (“FFCTO”).

 

The FFCTO was issued by the Ontario Securities Commission on April 8, 2024 against the Company for failing to file its Audited Annual Financial Statements and associated filings for the year ended December 31, 2023.

 

As of August 15, 2025, the Company is subject to restrictions on share issuances and certain types of payments as set out in the NEX policies. The trading symbol for the Company will change from SZLS to SZLS.H. There is no change in its CUSIP number and no consolidation of capital.

 

The Company will delist from trading on the Toronto Stock Exchange effective at the close on Thursday, August 14, 2025.

 

The NEX is a separate board of the TSX Venture Exchange. The NEX offers its listed companies support and visibility provided by a listing and trading environment tailored to their needs specifically while they are restructuring or financing prior to reactivating their full business.  Upon reactivation, the Company has the option of applying to list on the TSX or the TSX Venture exchanges.

 

Moving to the NEX offers the following benefits to Shareholders and the Company:

 

• Continued trading within the prestigious TMX Group of stock exchanges. Trading on NEX takes place on the same fully electronic system as TSX V and is governed by identical trading rules. 

• Streamlined filing obligations allowing more time for Company to focus on reactivation. Disclosure obligations remain the same. 

• An ability to raise capital with terms better suited to the Company’s current growth requirements. 

• Lower listing costs. 

 

The Company is pursuing financing opportunities to raise sufficient funds to pay the significant, outstanding fees to the auditors and, as a result, allow the Company to return to being compliant with the OSC filing requirements.  Additionally, a financing will allow the Company to scale and take full advantage of the partner opportunities it has secured, returning it to anticipated significant revenue generation. The Company is working with the OSC, TSX and NEX to effect the listing and financing permissions.

 

“We are pleased to have been accepted on the NEX.  We believe the exchange supports the Company at this particular growth stage.  We continue to work on the financing and the NEX listing is a positive step closer to concluding that.” said James Howard-Tripp, Chairman and CEO of StageZero Life Sciences.

 

The Company has spent the last 18 months diligently working to reduce overhead, streamline operations, and build partnerships that will strengthen the revenue funnel.  A lack of financing has significantly impacted and delayed the Company’s growth. That said, the Company now has a very streamlined operation and is scaling in the partnered opportunities with Aristotle, AVRT and the CareOncology Protocol.

 

As previously stated, the Company intends to use the proceeds of the Proposed Financing to (i) pay fees to its current and former auditors, accountants and other service providers, as well as audit, accounting, legal and filing fees to be incurred in preparing and filing all outstanding Documents, (ii) fulfill its operational and contractual commitments, and (iii) satisfy its operating expenses to ensure the continuity of the Company’s business during such time. The Company reasonably believes that the proceeds from the Proposed Financing will be sufficient to bring its continuous disclosure obligations up to date and pay all related outstanding fees and provide it with sufficient working capital to meet its obligations and continue its business during such period.

 

About StageZero Life Sciences, Ltd.

 

StageZero Life Sciences, Ltd. is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and unique telehealth programs that provide clinical interventions to assist patients who currently have cancer (COC Protocol) as well as help patients reduce the risk of developing late-stage disease (AVRT™).

 

The Company's next generation test, Aristotle®, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle® uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Sentinel Principle has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.

 

The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Developed by scientists and oncologists, the COC Protocol is intended for adjunctive administration alongside standard-of-care cancer therapy.

 

Aristotle®, as well as additional cancer diagnostics are processed at the Company's clinical laboratory, StageZero Life Sciences, Inc. in Richmond, Virginia.

 

SOURCE StageZero Life Science, Ltd.

 

Stay Connected

For more information about StageZero, visit www.StageZerolifesciences.com,

For further information please contact:
Investor Relations
Rebecca Greco
rgreco@stagezerols.com

 

Cautionary Note Regarding Forward-Looking Information and Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and includes statements concerning the Company’s intent to conduct the Proposed Financing, its belief that the proceeds will be sufficient to pay to bring its continuous disclosure record up to date, and its intent to file for a full revocation of the FFCTO, reinstatement of trading on the TSX, the ability to obtain the necessary approvals in connection with the Proposed Financing, and with respect to the timing for the filing of the Documents. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated March 31, 2023 filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com . The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.